51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY
Unregistered Sales of Equity Securities
Announces Strategic Review Process to Maximize Shareholder Value
Investor Presentation
Reports Second Quarter 2026 Results
2026 Annual Meeting Results; Directors Elected - Orly Mishan and Sean Salmon
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Reports First Quarter 2026 Results and Meaningful Clinical Progress Advancing Toward Submission for PMA Approval Following Late-Breaking FULCRUM-VT Data
Q2
Amended Annual Report
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-8 POS